704 related articles for article (PubMed ID: 19489652)
21. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
22. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.
Ajeganova S; Fiskesund R; de Faire U; Hafström I; Frostegård J
Clin Exp Rheumatol; 2011; 29(6):942-50. PubMed ID: 22153361
[TBL] [Abstract][Full Text] [Related]
23. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
[TBL] [Abstract][Full Text] [Related]
24. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
Nurmohamed MT
Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
[TBL] [Abstract][Full Text] [Related]
25. Sequential use of biologic therapy in rheumatoid arthritis.
Buch MH
Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
[TBL] [Abstract][Full Text] [Related]
26. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.
Lutt JR; Deodhar A
Drugs; 2008; 68(5):591-606. PubMed ID: 18370440
[TBL] [Abstract][Full Text] [Related]
27. The use of biologic therapies in the treatment of rheumatoid arthritis.
Wang D; Li Y; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
[TBL] [Abstract][Full Text] [Related]
28. [New therapies for rheumatoid arthritis].
Salgado E; Maneiro JR
Med Clin (Barc); 2014 Nov; 143(10):461-6. PubMed ID: 24461738
[TBL] [Abstract][Full Text] [Related]
29. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
[TBL] [Abstract][Full Text] [Related]
30. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
31. [Biological treatment options for Graves' ophthalmopathy].
El Fassi D; Nielsen CH; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
[TBL] [Abstract][Full Text] [Related]
32. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.
Rubbert-Roth A; Finckh A
Arthritis Res Ther; 2009; 11 Suppl 1(Suppl 1):S1. PubMed ID: 19368701
[TBL] [Abstract][Full Text] [Related]
33. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
[TBL] [Abstract][Full Text] [Related]
34. [New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):149-59. PubMed ID: 19564711
[TBL] [Abstract][Full Text] [Related]
35. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
Yuan Y; Trivedi D; Maclean R; Rosenblatt L
J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
[TBL] [Abstract][Full Text] [Related]
36. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J; Krüger K
Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
[TBL] [Abstract][Full Text] [Related]
37. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
Astorri E; Nerviani A; Bombardieri M; Pitzalis C
Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Siddiqui MA
Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
[TBL] [Abstract][Full Text] [Related]
39. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
40. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
